New leukaemia treatment from Janssen approved

chronic lymphatic leukaemia (new treatment from Janssen)
A new targeted anti-cancer therapy that helps improve survival in the most common form of leukaemia, Chronic Lymphocytic Leukaemia, has received regulatory approval in Australia. The treatment, from Janssen, is approved for Australians with CLL who have received at least one prior therapy or who have a chromosome anomaly known as 17p deletion. IMBRUVICA (ibruntinib)

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Debra Rowett elected president of Australian Pharmacy Council
Next Drugs save sight in macular degeneration: RANZCO